Clinical Research Directory

Inclusion Criteria: * Men with histologically confirmed prostate cancer * Men who have undergone radical prostatectomy (RP), with or without extended pelvic lymph node dissection (ePLND) * Men with pNx or pN0 status in the ePLND specimen * Biochemical recurrence after RP (PSA \> 0.2 ng/mL on two occasions) * Evidence of lymphogenic metastases on staging PSMA PET/CT within the pelvis (below the aortic bifurcation) * Life expectancy ≥ 5 years, as estimated by the treating physician Exclusion Criteria: * Previous salvage radiotherapy to the prostate bed * Men with lymph node metastases outside the pelvis (M1a) * Men with osseous metastases (M1b) or visceral metastases (M1c) * Men with lymphogenic metastases and a local recurrence * Men with inguinal metastases * Previous treatment in the pelvic region, such as treatment of the bladder or rectum, that precludes radiotherapy to the pelvis * Previous treatment with an LHRH agonist/antagonist within 6 months prior to study inclusion. Patients must have normal testosterone levels (testosterone \> 7.0 nmol/L)